Predilife S.A. (EPA: ALPRE)

Market Cap	13.53M
Revenue (ttm)	300.87K
Net Income (ttm)	-4.66M
Shares Out	3.72M
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	799
Open	3.800
Previous Close	3.800
Day's Range	3.660 - 3.800
52-Week Range	3.320 - 24.000
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 25, 2025

About Predilife

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALPRE

Financial Performance

In 2023, Predilife's revenue was 317,794, an increase of 10.11% compared to the previous year's 288,602. Losses were -4.22 million, 15.6% more than in 2022.